High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection

Eur J Med Res. 2022 Sep 16;27(1):180. doi: 10.1186/s40001-022-00809-6.

Abstract

Background: Hepatitis C virus (HCV) infection is a serious public health concern due to its high prevalence and mortality rate. In chronic infection, HCV may induce autoimmune responses through the production of autoantibodies, including antinuclear antibodies (ANA).

Methods: We assessed the presence of ANA by indirect immunofluorescence using HEp-2 cells in 89 patients with chronic hepatitis C. We also collected data on epidemiological variables; clinical characteristics; and biochemical, hematological, molecular, and histopathological information from the patients to assess the impact of the presence of ANA in those patients.

Results: The prevalence of ANA in the patients was 20.2%, which was significantly higher than that found in healthy controls (2%). However, there was no association of this marker with epidemiological, clinical-laboratory, molecular or histopathological characteristics of hepatitis C, although a slightly higher prevalence of ANA was detected in women and in patients infected with subgenotype 1a. In a specific analysis, chronic HCV patients with the "rods and rings" cytoplasmic pattern had higher degrees of hepatic fibrosis than did ANA-negative patients.

Conclusions: The results confirm a greater predisposition to the presence of ANA in patients with HCV, which may be associated with a worse prognosis, especially in the presence of the "rods and rings" cytoplasmic pattern.

Keywords: ANA; Autoantibodies; Genotypes; HCV.

MeSH terms

  • Antibodies, Antinuclear
  • Autoantibodies
  • Female
  • Hepacivirus / genetics
  • Hepatitis C*
  • Hepatitis C, Chronic* / epidemiology
  • Humans
  • Prevalence

Substances

  • Antibodies, Antinuclear
  • Autoantibodies